NIPPON SHINYAKU CO., LTD.







INTEGRATED REPORT 2026

A New Way of Life









Contents

INTRODUCTION

01 Contents
03 Our Philosophy
04 About Nippon Shinyaku
05 A Century of Progress Built on the Challenge of Drug Discovery
06 Addressing the Challenge of Intractable and Rare Diseases
07 Message from the President
11 Global Growth Strategy

Strengths of Nippon Shinyaku

14 Three Strengths Underpinning Our Value Creation
15 Special Feature: One-Team Approach
18 Material Issues
21 Management Capital That Supports Value Creation
22 Value Creation Process

Strategies and Initiatives for Value Creation

24 Evolution of the Medium-Term Management Plan (MTMP)
25 7th Five-Year Medium-Term Management Plan
27 Financial and Capital Strategy
31 Realizing a Healthy Future by Creating Innovation
31 — Pharmaceuticals Business
37 — Functional Food Business
39 — Digital Transformation (DX)
40 Developing Diverse Human Resources and Realizing Employee Well-being
45 Resolving Social Issues and Coexisting with the Community
47 Strengthening Efforts to Protect the Global Environment

Management Foundation for Value Creation

52 Message from the Chairman
53 Strengthening Governance
60 Special Feature: Governance That Supports Taking on Challenges, and the Effectiveness of the Board of Directors
63 Management Team
65 Compliance and Risk Management
67 Stakeholder Engagement

Corporate Data

69 Financial Highlights
70 Non-Financial Highlights
71 Eleven-Year Financial Data
73 Non-Financial Data
75 Corporate Profile/Investor Information

Editorial Policy

This report provides comprehensive coverage of non-financial information, including the environment, society, and governance, in addition to financial information so that all of our stakeholders can understand the corporate value of the Nippon Shinyaku Group.

Guidelines Referenced

- Integrated Reporting Framework, International Sustainability Standards Board (ISSB)
- GRI Standards
- Guidance for Collaborative Value Creation, Ministry of Economy, Trade and Industry

Forward-Looking Statements

Statements contained in this report concerning plans, predictions, and strategies to improve future performance ("forward-looking statements") are based on information currently available to the Company's management, and inevitably involve a certain element of risk and uncertainty. Actual results may therefore differ from those in the forward-looking statements. This report contains information about the Company's pharmaceuticals (including products in development); this information is not intended to function as a promotion or medical advice.

* As figures presented in this report have been rounded, totals may not exactly equal the sum of their composite figures.
* Product names featured in the report are registered trademarks of Nippon Shinyaku or affiliated companies.
* All information in this report, including comments, has been obtained in an appropriate manner.

Scope of Reporting

Period covered: Fiscal 2025 (April 1, 2025 – March 31, 2026)
* Some sections of the report discuss initiatives from April 2026 onwards.

Companies covered: Nippon Shinyaku Co., Ltd. and its Japanese and overseas Group Companies
* However, some sections of the report only cover Nippon Shinyaku Co., Ltd.

Relevant Information

Sustainability/ESG information

- Website: Sustainability
- Human Capital Report
- Corporate Governance Basic Policy
- Corporate Governance Report
- ESG Data
- GRI Standard Content Table

Information for shareholders and investors

- Website: Investor Relations
- Annual Securities Report*
- Financial Summary*
- Management Policy and Plan (Medium-Term Management Plan)
- Shareholder Communications

* All statutory disclosure/timely disclosure documents and other disclosure materials are available on the Company's website.